Erectile dysfunction: a warning sign of silent vascular disease

Paraskevas, Kosmas I.; Koupidis, Sotirios A; Mikhailidis, Dimitri P.; Oreopoulos, Dimitrios G.

doi:10.1007/s11255-009-9630-1

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ED is a prevalent and chronic disorder of aging male [24]. CV disease and ED often have the same etiology when endothelial dysfunction and atherosclerosis affect both coronary arteries and penile vasculature [25–28]. In the daily practice, urologists usually try to modulate the endothelial function with the PDE5 inhibitors, but vascular impairment through hyperlipidemia, apart from effects of diabetic mellitus, is thought to be responsible for 40% of ED presentations.…”

Section: Discussionmentioning

confidence: 99%

The Effect of Statins on Erectile Dysfunction: A Systematic Review and Meta-Analysis

Cui

Zong

Yan

et al. 2014

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction It is not known if statins will improve symptoms in patients with established erectile dysfunction (ED). Aim We carried out a systematic review and meta-analysis to assess the effect of statins on ED. Methods A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of statins for the treatment of ED. The search included the following databases: MEDLINE, Embase, and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. A systematic review and meta-analysis were conducted. Main Outcome Measures Six publications involving a total of 462 patients were used in the analysis, including three randomized controlled trials (RCTs) that compared statins with placebo and three RCTs that compared statins plus sildenafil with placebo plus sildenafil. Results For the comparison of statins (+/− sildenafil) with placebo (+/− sildenafil), the mean International Index of Erectile Function (IIEF-5) (the standardized mean difference [SMD] = 3.23, 95% confidence interval [CI] = −1.65 to 4.80, P < 0.0001) indicated that statins (+/− sildenafil) showed statistically significantly greater improvements in the mean IIEF-5 compared with placebo (+/− sildenafil). For the comparison of statins with placebo, the mean IIEF-5 (SMD = 2.13, 95% CI = −1.46 to 5.73, P = 0.24) indicated that there was no significant difference in erectile function between the statins and placebo. For the comparison of statins plus sildenafil with placebo plus sildenafil, the mean IIEF-5 (SMD = 3.60, 95% CI = 2.64 to 4.56, P < 0.00001), the IIEF domain (SMD = 4.88, 95%CI = 3.01 to 6.74, P < 0.00001), and the global efficacy question (odds ratio = 6.44, 95% CI = 2.92 to 14.23, P < 0.00001) showed that compared with placebo plus sildenafil, statins plus sildenafil clearly improved erectile function. Conclusions This meta-analysis indicates that statins (+/− sildenafil) may improve ED compared with placebo (+/− sildenafil).

show abstract

Section: Discussionmentioning

confidence: 99%

The Effect of Statins on Erectile Dysfunction: A Systematic Review and Meta-Analysis

Cui

Zong

Yan

et al. 2014

The Journal of Sexual Medicine

View full text Add to dashboard Cite

show abstract

“…They found that most of the patients who were found to have CAD also had ED, and in 70% of them, ED was present before anginal symptoms became evident [11]. Thus, we thought that the interrogation of patients with chest pain about the presence and Endothelial dysfunction is the key event in the pathophysiology of ED and, importantly, men with penile vascular dysfunction have endothelial dysfunction in other vascular beds as well [15][16][17]. Furthermore, the small diameter of the cavernosal arteries and the high content of endothelium per gram of tissue (compared with other organs) may make the penile vascular bed a sensitive and early indicator of systemic vascular disease [18].…”

Section: Discussionmentioning

confidence: 99%